🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsMy pharmacist tried to explain the mechanism and my eyes glazed over — looking for input

My pharmacist tried to explain the mechanism and my eyes glazed over — looking for input

hannah_MT Thu, Jan 9, 2025 at 3:59 AM 13 replies 1,633 viewsPage 1 of 3
This thread is more than 17 months old. Information may be outdated. Consider searching for more recent discussions.
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Jan 9, 2025 at 3:59 AM#1

Writing this once so I can stop repeating it across threads. It is about the pharmacology, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

The condition it depends on

The adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.

The practical version

Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

What I am not sure about

The narrow version of the question is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Happy to be told the question itself is wrong.

— hannah_MT · corrections welcome and will be edited into this post with credit
21 16nick_newbie, DadBodDave, AmyNC_wife and 18 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Jan 9, 2025 at 4:05 AM#2
hannah_MT said:
The mechanism is more central than most summaries suggest.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
Last edited: Jan 9, 2025 at 6:05 AM
20 15NauseaFreeNow, SteveThurs, B12Beth and 17 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Jan 9, 2025 at 4:11 AM#3
hannah_MT said:
The mechanism is more central than most summaries suggest.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Last edited: Jan 9, 2025 at 5:11 AM
19 14mark_tokyo, hans_munich, jason_sac26 and 16 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Jan 9, 2025 at 4:17 AM#4
Dr.RaviCardio said:
The pharmacokinetics explain nearly every practical question asked here.

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

References:
[1] Lau J, et al. J Med Chem. 2015;58(18):7370-7380.
18 13PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 15 others
Reply Quote Save Share Report
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Jan 9, 2025 at 4:45 AM#5
Dr.NateNeph said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

Last edited: Jan 9, 2025 at 10:45 AM
17 12NauseaFreeNow, SteveThurs, B12Beth and 14 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register